本文選題：phosphodiesterase + phosphoproteome��； 參考：《中國藥理學與毒理學雜志》2017年05期

【摘要】：We now know that 11 different families of cyclic nucleotide phosphodiesterases(PDEs) are expressed in mammalian species. Most of these families contain multiple gene products and most of the genes utilize alternative splicing or alternative start sites to encode more than one RNA/protein.However,specific functions for these different PDEs have not yet been identified in most cell types despite the fact that selective inhibitors to most of the PDE families are available. Conventional approaches to study PDE function typically rely on measurements of global cAMP,or general increases in cAMP-dependent protein kinase A(PKA),or exchange protein activated by cAMP(EPAC) activity.Although newer approaches utilizing subcellularly-targeted FRET reporter sensors have helped to define more compartmentalized regulation of cAMP,PKA,and EPAC,they have limited ability to link this regulation to downstream effector molecules and biological functions. To address this problem,we have begun to use an unbiased,mass spectrometry-based approach coupled with treatment using PDE isozyme-selective inhibitors to characterize the phosphoproteomes of the ″ functional pools″ of cAMP that are regulated by specific cAMP-PDEs(the PDE-regulated phosphoproteomes). In MA-10 Leydig cells we find that in order to detect appreciable increased in either phosphorylation or steroid production,one needs to inhibit both PDE 4 and PDE 8 activity.Using this combination of inhibitors,we find large PDE inhibitor-induced changes in many different proteins that modulate steroid trafficking and biosynthesis. The data are consistent with the idea that cAMP serves to coordinate hormone stimulation of steroid production by altering the phosphorylation of many different proteins at multiple points in the overall pathway rather than just controlling a single rate limiting step. It seems quite likely that many of the proteins phosphorylated in this cell type in response to PDE inhibition,will also be regulated by cAMP in many other cell types.Similarly,in Jurkat cells we find multiple,distinct,PDE regulated phosphoproteomes that differ in response to different PDE inhibitors. Here we also find that little phosphorylation occurs unless at least 2 different PDEs are concurrently inhibited in these cells. Inhibition of a single PDE produces little effect. Bioinformatics analyses of these phosphoproteomes suggest differing functional roles,mechanisms of action,and synergistic relationships among the different PDEs that coordinate cAMP-signaling cascades in these cells. In this tissue also,the data strongly imply that phosphorylation of many different substrates contribute to cAMP-dependent regulation of these cells. Overall,the findings illustrate that the approach of using selective,inhibitor-dependent phosphoproteome analysis can provide a generalized methodology for understanding the roles of different PDEs in the regulation of cyclic nucleotide signaling.
[Abstract]:We now know that 11 different families of cyclic nucleotide phosphodiesteras esp are expressed in mammalian species. Most of these families contain multiple gene products and most of the genes utilize alternative splicing or alternative start sites to encode more than one RNA/protein.However,specific functions for these different PDEs have not yet been identified in most cell types despite the fact that selective inhibitors to most of the PDE families are available. Conventional approaches to study PDE function typically rely on measurements of global cAMPP or general increases in cAMP-dependent protein kinase PKA or exchange protein activated by cAMP / EPAC) activity.Although newer approaches utilizing subcellularly-targeted FRET reporter sensors have helped to define more compartmentalized regulation of cAMP / PKA and EPAC / have limited ability to link this regulation to downstream effector molecules and biological functions. To address this problemwe have begun to use an unbiasedmass spectrometry-based approach coupled with treatment using PDE isozyme-selective inhibitors to characterize the phosphoproteomes of the "functional pools" of cAMP that are regulated by specific cAMP-PDEs(the PDE-regulated phosphoproteomes. In MA-10 Leydig cells we find that in order to detect appreciable increased in either phosphorylation or steroid production,one needs to inhibit both PDE 4 and PDE 8 activity.Using this combination of inhibitors,we find large PDE inhibitor-induced changes in many different proteins that modulate steroid trafficking and biosynthesis. The data are consistent with the idea that cAMP serves to coordinate hormone stimulation of steroid production by altering the phosphorylation of many different proteins at multiple points in the overall pathway rather than just controlling a single rate limiting step. It seems quite likely that many of the proteins phosphorylated in this cell type in response to PDE inhibition,will also be regulated by cAMP in many other cell types.Similarly,in Jurkat cells we find multiple,distinct,PDE regulated phosphoproteomes that differ in response to different PDE inhibitors. Here we also find that little phosphorylation occurs unless at least 2 different PDEs are concurrently inhibited in these cells. Inhibition of a single PDE produces little effect. Bioinformatics analyses of these phosphoproteomes suggest differing functional roles,mechanisms of action,and synergistic relationships among the different PDEs that coordinate cAMP-signaling cascades in these cells. In this tissue also,the data strongly imply that phosphorylation of many different substrates contribute to cAMP-dependent regulation of these cells. Over the findings illustrate that the approach of using selectiveor dependent phosphoproteome analysis can provide a generalized methodology for understanding the roles of different PDEs in the regulation of cyclic nucleotide signaling.
【作者單位】： University
【分類號】：R3411

【相似文獻】

相關期刊論文 前7條

1 陳麗;李紅梅;夏高曉;趙明哲;胡水旺;王繼剛;徐佳;劉靖華;鄧鵬;姜勇;;小鼠肝細胞線粒體磷酸化蛋白質(zhì)組的初步研究[J];解放軍醫(yī)學雜志;2009年02期

2 劉鑫;唐圣松;;酸性核糖體磷酸化蛋白P0的研究進展[J];現(xiàn)代醫(yī)藥衛(wèi)生;2010年01期

3 王少東,樊代明;耐藥細胞中的磷酸化蛋白[J];臨床腫瘤學雜志;1997年04期

4 李洪;肖穎彬;楊天德;牟芝蓉;鄒麗云;黃河;;二氮嗪預處理心肌細胞后磷酸化蛋白質(zhì)組差異表達的初步研究[J];中國病理生理雜志;2007年05期

5 胡斌;田曉慧;孟祥軍;;高爾基體磷酸化蛋白GOLPH2的研究及其潛在的應用價值[J];現(xiàn)代生物醫(yī)學進展;2013年26期

6 孫雪敏,余應年,陳星若;甲基硝基亞硝胍處理的vero細胞中磷酸化蛋白的差異顯示[J];中國病理生理雜志;1999年02期

7 ;[J];;年期

相關會議論文 前3條

1 張鍇;何錫文;;質(zhì)譜技術鑒定激酶中非磷酸化蛋白修飾[A];第十屆中國化學會分析化學年會暨第十屆全國原子光譜學術會議論文摘要集[C];2009年

2 王京蘭;郭立海;張養(yǎng)軍;蔡耘;錢小紅;;人胎肝細胞膜提取蛋白質(zhì)的磷酸化蛋白質(zhì)組分析[A];中國蛋白質(zhì)組學第二屆學術大會論文摘要論文集[C];2004年

3 王蔚;劉蕓;康瑞霞;陳麗;夏高曉;鄧鵬;姜勇;;細胞氧化應激過程中MK2調(diào)控磷酸化蛋白的鑒定[A];中國病理生理學會受體、腫瘤和免疫專業(yè)委員會聯(lián)合學術會議論文匯編[C];2010年

相關博士學位論文 前2條

1 王京蘭;磷酸化蛋白質(zhì)分析方法研究及其在人胎肝磷酸化蛋白質(zhì)組研究中的應用[D];中國人民解放軍軍事醫(yī)學科學院;2004年

2 隋少卉;磷酸化蛋白質(zhì)組學定性與定量分析技術的研究及在肝細胞磷酸化蛋白質(zhì)組學中的應用[D];中國人民解放軍軍事醫(yī)學科學院;2007年

相關碩士學位論文 前1條

1 陳涌;不同溫度下福氏志賀菌磷酸化蛋白質(zhì)組的比較差異研究[D];北京協(xié)和醫(yī)學院;2014年

，

本文編號：1991716